Insider Selling: GSK plc (LON:GSK) Insider Sells £545,348.62 in Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 38,459 shares of the business’s stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($17.94), for a total value of £545,348.62 ($690,139.99).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The stock was sold at an average price of GBX 1,453 ($18.39), for a total value of £1,753,088.09 ($2,218,537.19).

GSK Stock Down 1.2 %

Shares of LON GSK opened at GBX 1,429 ($18.08) on Monday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The stock has a 50-day simple moving average of GBX 1,377.06. GSK plc has a 52-week low of GBX 1,282.50 ($16.23) and a 52-week high of GBX 1,823.50 ($23.08). The company has a market capitalization of £57.99 billion, a PE ratio of 23.08, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities research analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. Berenberg Bank dropped their price objective on GSK from GBX 1,820 ($23.03) to GBX 1,600 ($20.25) and set a “buy” rating for the company in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.85).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.